Research programme: cancer vaccines - OnyvaxAlternative Names: Onyvax-L; Onyvax-M; Onyvax-R
Latest Information Update: 01 Jun 2010
At a glance
- Originator Onyvax
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Lung cancer; Multiple myeloma; Renal cancer
Most Recent Events
- 05 Mar 2004 This compound is still in active development
- 13 Feb 2003 Preclinical trials in Renal cancer in United Kingdom (unspecified route)